Category: Tuberculosis
| Intervention | Condition | Outcome / Effect | Source | ||
|---|---|---|---|---|---|
| 📊 |
Systematic testing and treatment of late
vs No systematic testing and trea |
Latent Tuberculosis Infection
High-risk individuals |
Systematic testing and treatment of LTBI in high-risk groups (people living with HIV, adult and chil | ↑ | 4664608 |
| 📊 |
LTBI - Latent tuberculosis infection
vs No LTBI treatment |
Latent Tuberculosis Infection
Nutrition skill of supportive |
LTBI treatment with isoniazid and/or rifamycins does not significantly increase the risk of anti-TB
relative risk of rifamycin resistance 1. |
— | 4664608 |
| 📊 |
scale-up of targeted latent tuberculosis
vs other LTBI regimens (e.g., rif |
Latent Tuberculosis Infection
At-risk populations |
Isoniazid monotherapy was associated with lower completion rates of LTBI treatment compared to other
456/807 (57%) completed Side effects: 19/495 (4%) discontinued due to side effects (all |
↓ |
5614812
up to 4 years |
| 📊 |
LTBI - Latent tuberculosis infection
vs N/A |
Latent Tuberculosis Infection
People |
Only 63% of persons initiating therapy for LTBI completed treatment.
723/1,147 (63%) completed |
— |
5614812
up to 4 years |
| 📊 |
LTBI - Latent tuberculosis infection
vs N/A |
Latent Tuberculosis Infection
People |
4% of contacts discontinued LTBI treatment due to adverse events.
19/495 (4%) discontinued due to side eff Side effects: 19/495 (4%) discontinued due to side effects |
↓ |
5614812
up to 4 years |
| 📊 |
LTBI - Latent tuberculosis infection
vs N/A |
Latent Tuberculosis Infection
High-risk populations |
The most common reasons for LTBI treatment non-completion were loss-to-follow-up (46%), non-adherenc
Most common reasons: loss-to-follow-up ( |
↓ |
5614812
up to 4 years |
| 📊 |
Latent tuberculosis infection treatment
vs no treatment |
Latent Tuberculosis Infection
Nutrition skill of supportive |
Currently advocated regimens for latent tuberculosis infection (LTBI) reduce progression to active t
efficacy ranging from 60-90% |
↑ | 6354243 |
| 📊 | flight-related tuberculosis contact inve | Latent Tuberculosis Infection
Airline passengers exposed to |
The cost per person of treating latent tuberculosis infection was $949.51 for a full (270 doses) tre
$949.51 for full (270 doses) treatment c |
— |
5451105
Modeled lifetime ris |
| 📊 |
scale-up of targeted latent tuberculosis
vs other LTBI regimens (e.g., rif |
Tuberculosis
At-risk populations |
Isoniazid monotherapy was associated with lower completion rates of LTBI treatment compared to other
456/807 (57%) completed Side effects: 19/495 (4%) discontinued due to side effects (all |
↓ |
5614812
up to 4 years |
| 📊 |
Latent tuberculosis infection treatment
vs no treatment |
Tuberculosis
Nutrition skill of supportive |
Currently advocated regimens for latent tuberculosis infection (LTBI) reduce progression to active t
efficacy ranging from 60-90% |
↑ | 6354243 |
| 📊 | flight-related tuberculosis contact inve | Tuberculosis
Airline passengers exposed to |
The cost per person of treating latent tuberculosis infection was $949.51 for a full (270 doses) tre
$949.51 for full (270 doses) treatment c |
— |
5451105
Modeled lifetime ris |
| 📊 |
completion of latent tuberculosis infect
vs no LTBI treatment completion |
Tuberculosis
Airline passengers exposed to |
Persons completing latent tuberculosis infection treatment reduced their risk of progression to tube
80% reduction in risk of progression to |
↑ |
5451105
Modeled lifetime ris |
| 📊 |
Latent tuberculosis infection in HIV-inf
vs HIV-uninfected persons with LT |
Tuberculosis
HIV-infected persons |
Among HIV-infected persons with LTBI, the rate of reactivation TB was estimated as 1.82 cases per 10
1.82 cases per 100 person-years |
↓ |
5547435
3 years |
| 📊 |
Latent tuberculosis infection treatment
vs no treatment |
Drug-sensitive tuberculosis
Nutrition skill of supportive |
Currently advocated regimens for latent tuberculosis infection (LTBI) reduce progression to active t
efficacy ranging from 60-90% |
↑ | 6354243 |
Currently advocated regimens for latent tuberculosis infection (LTBI) typically involve treatment durations that provide 60-90% efficacy in reducing progression to active tuberculosis, though the specific duration is not stated here (commonly 3-9 months depending on regimen). (6354243) A full course of LTBI treatment is often defined as 270 doses, which corresponds to approximately 9 months of daily isoniazid therapy. (5451105) Completion of the recommended LTBI treatment course reduces the risk of progression to active tuberculosis by 80% compared to those who do not complete treatment. (5451105)